Close

Xencor (XNCR) Plans to Present Final Results from Phase 2 Study of XmAb5871 in IgG4-Related Disease at ACR

October 20, 2017 4:01 PM EDT Send to a Friend
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login